Cargando…

P969: VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY

Detalles Bibliográficos
Autores principales:	Nordberg Nørgaard, Jakob, Falck Moore, Kari Lenita, Slørdahl, Tobias, Vik, Anders, Tvedt, Tor Henrik Anderson, Schjesvold, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431519/ http://dx.doi.org/10.1097/01.HS9.0000970780.55147.2c

Ejemplares similares

PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.
por: Novosad, Olga, et al.
Publicado: (2023)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

A Comparison of 12 Weeks of Pilates and Aquatic Training on the Dynamic Balance of Women with Mulitple Sclerosis
por: Marandi, Sayyed Mohammad, et al.
Publicado: (2013)

Run 969, 26 GeV/c
por: Vos, L
Publicado: (1978)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Comparison of [(18)F]fluciclovine and [(18)F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
por: Stokke, Caroline, et al.
Publicado: (2022)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2016)

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
por: Bugge Askeland, Frida, et al.
Publicado: (2023)

Neoplastic plasma cells with Auer rod‐like inclusions
por: Jakob, Nordberg Nørgaard, et al.
Publicado: (2020)

VCD Studies on Chiral Characters of Metal Complex Oligomers
por: Sato, Hisako, et al.
Publicado: (2013)

Endocrine profile of the VCD-induced perimenopausal model rat
por: Carolino, Ruither O. G., et al.
Publicado: (2019)

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
por: Borisov, Nicolas, et al.
Publicado: (2021)

P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
por: Askeland, F. B., et al.
Publicado: (2022)

P969: COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS
por: Wang, Y., et al.
Publicado: (2022)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

MD run 969, 26 GeV/c, 1/9/78
por: Jacquiot, P
Publicado: (1978)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
por: Nakaya, Aya, et al.
Publicado: (2021)

Toxic effects of VCD on kidneys and liver tissues: a histopathological and biochemical study
por: Ahmadian, Shahin, et al.
Publicado: (2019)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Teoría y metodología de las técnicas de diagnóstico y multicolinealidad en el análisis de regresión lineal múlitple : una aplicación práctica
por: Landa Castañeda, Nadya Elena
Publicado: (2003)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
por: Behling, Felix, et al.
Publicado: (2016)

Health behaviours and fear of cancer recurrence in 10 969 colorectal cancer (CRC) patients
por: Fisher, A., et al.
Publicado: (2016)

969. Antibiotic Prescribing in a Large Retail Health Clinic Chain: Opportunities for Stewardship
por: Fleming-Dutra, Katherine E, et al.
Publicado: (2019)

Experimental prospects for Vud , Vus , Vcd , Vcs and (semi-)leptonic D decays at LHCb
por: Davis, Adam
Publicado: (2018)

Improving the IR spectra alignment algorithm with spectra deconvolution and combination with Raman or VCD spectroscopy
por: Böselt, Lennard, et al.
Publicado: (2022)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
por: Nameera, Rahmathullah Sulaimankutty, et al.
Publicado: (2023)

969 Macrolide resistant mycoplasma did not have worse clinical course in children's hospital in Japan
por: Funakoshi, Yu, et al.
Publicado: (2014)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Speech Therapy Telepractice for Vocal Cord Dysfunction (VCD): MaineCare (Medicaid) Cost Savings
por: Towey, Michael P.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_33o4ftiu93q1pvd5vbkeb4suqi